Breaking News

Rithem Life Sciences Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

1st Patients Enrolled in STEM Trial for `Treatment of Chronic Subdural Hematoma

This marks the first patients enrolled in a prospective, randomized, international trial of a liquid embolic agent for the treatment of chronic subdural hematoma (cSDH), a common disease affecting primarily older adults.

Genius AI Detection Receives FDA Clearance – New Deep Learning-based Software Designed to Help Radiologists Detect Subtle Potential Cancers in Breast Tomosynthesis Images

This new technology, represents a pivotal milestone in the early detection of breast cancer, as studies showed Genius AI Detection software aids in the identification and early detection of breast cancer when used with the Genius® 3D Mammography™ exam.

Passio Pump Drainage System Granted 510(k) for Additional Indication for Home Use

The Passio Pump Drainage System consists of the Passio Catheter, a Handheld Control Unit (pump) and a Disposable Collection Kit, which includes a redressing kit, for drainage of recurrent and symptomatic pleural effusion.

Boston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business

Boston Scientific notes SERB, backed by private equity firm Charterhouse Capital Partners since 2017, owns a diversified portfolio of prescription medicines focused on rare and life-threatening diseases.

Hologic Launches its First Cart-Based Ultrasound System, SuperSonic™ MACH 40

Today announced today the U.S. launch of the SuperSonic™ MACH 40 ultrasound system, expanding the Company’s suite of ultrasound technologies with its first premium, cart-based system. The new system features excellent image quality, standard-setting imaging modes, and is designed to enhance efficiency and accuracy.

“As the leader in breast imaging, we’re committed to delivering insight-driven solutions that optimize patient care across the full continuum of care for breast health – from screening to treatment,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions. “With the addition of the SuperSonic MACH 40 system, we’ve successfully built a comprehensive portfolio of innovative, standard-setting breast ultrasound solutions designed to better meet the needs of breast imagers. The SuperSonic MACH 40 system embodies our commitment to delivering future-oriented solutions and was designed to help healthcare professionals reduce unnecessary biopsies by eliminating re-scans, reducing lesion correlation time, and improving overall diagnostic accuracy.”

The SuperSonic MACH 40 system leverages exclusive UltraFast™ imaging technology – inspired by cutting-edge graphics innovations from the video gaming industry – to provide greater frame rates of up to 20,000 images per second1. The technology also enables innovative imaging modes, without the trade-offs present in conventional systems. This forward-thinking, powerful architecture primes the system for future integrations and AI-driven innovations.

The new system is further enhanced by exceptional B-mode imaging technology, which helps improve diagnostic confidence thanks to smoother images with reduced speckle, clearer images across all tissue densities, and improved lesion conspicuity. It also features the third generation of shear wave-based elastography technology, ShearWave™ PLUS, which provides additional diagnostic information that may help with patient management, including diagnostic workup of breast lesions, lesion targeting during ultrasound-guided biopsy, and lesion size measurement. Three innovative imaging modes come together in TriVu™ imaging, where morphology, stiffness and blood flow can all be analyzed simultaneously in the same image.

“Hologic continues to expand its portfolio with the patient and clinician in mind, and that’s apparent with the recent SuperSonic Imagine acquisition and new innovations,” said Stacy Smith-Foley, MD, Medical Director of The Breast Center at CARTI in Little Rock, AR. “The result has been a consistently growing suite of tools that truly complement each other and help me and my colleagues to efficiently care for our patients on a day-to-day basis across the entire breast health continuum.”

Clinicians performing precision-dependent ultrasound-guided biopsies with the SuperSonic MACH 40 system can also enjoy enhanced control with Needle PL.U.S. imaging, which enables visualization of both the biopsy needle and anatomical structures in real time and predicts the needle trajectory.

The SuperSonic MACH 40 system streamlines workflow with intuitive design and enhanced comfort. Thanks to the SonicPad™ multi-touch trackpad, the new system helps physicians focus on imaging without the distractions of unnecessary user movements, thus enhancing workflow and increasing patient throughput.

The SuperSonic MACH 40 system is part of a growing portfolio of ultrasound solutions resulting from Hologic’s recent acquisition of SuperSonic Imagine, a pioneer in the field of ultrasound imaging. For more information about the SuperSonic MACH 40 ultrasound system, visit hologic.com/ultrasound/MACH-40.


1 Ultrafast Ultrasound Imaging, by Jeremy Bercoff (Published: August 23 2011 DOI: 10.5772/19729)

Latest Posts

Rithem Life Sciences Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

1st Patients Enrolled in STEM Trial for `Treatment of Chronic Subdural Hematoma

This marks the first patients enrolled in a prospective, randomized, international trial of a liquid embolic agent for the treatment of chronic subdural hematoma (cSDH), a common disease affecting primarily older adults.

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

Don't Miss

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. 

Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreen to accelerate in China.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials.